Prosecution Insights
Last updated: April 19, 2026

Examiner: BROWN, DALIYAH MONYHE

Tech Center 1600 • Art Units: 1654

This examiner grants 100% of resolved cases

Performance Statistics

100.0%
Allow Rate
+40.0% vs TC avg
10
Total Applications
+100.0%
Interview Lift
1175
Avg Prosecution Days
Based on 1 resolved cases, 2023–2026

Rejection Statute Breakdown

6.1%
§101 Eligibility
15.2%
§102 Novelty
33.3%
§103 Obviousness
33.3%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18260190 CO-FORMULATION OF POLYMYXINS FOR INHALATION Non-Final OA Purdue Research Foundation
18546477 TIRZEPATIDE THERAPEUTIC METHODS Non-Final OA Eli Lilly and Company
18279772 NLRP3 INFLAMMASOME INHIBITORY PEPTIDE FOR TREATMENT OF INFLAMMATORY DISEASES Non-Final OA AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
18556772 PEPTIDES INHIBITING COVID-19 Non-Final OA QUANTBIORES A/S
18550807 PROTEINS AND USES THEREOF Non-Final OA Macrobiome Therapeutics Pty Ltd
18320895 METHOD FOR REPAIRING SERTOLI CELL INJURY IN TESTES Non-Final OA The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University
18317002 NOVEL FORMULATIONS FOR ORAL ADMINISTRATION OF THERAPEUTIC AGENTS TO THE GASTROINTESTINAL TRACT Non-Final OA Hôpital Lyon Sud, HOSPICES CIVILS DE LYON
18309154 COMPOSITIONS COMPRISING AAV-BINDING POLYPEPTIDES AND METHODS OF USING THE SAME Non-Final OA Isolere Bio, Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month